Dr. Manasi Shah

Dr. Manasi Shah is a US-trained Medical Oncologist with extensive experience across leading institutions in the United States and India. She has served in academic, clinical, and research roles at Yale-affiliated Bridgeport Hospital, University of Connecticut, and NewYork-Presbyterian Medical Group. She treats solid tumours, with a special area of interest in breast and gynaecological oncology. Her clinical practice integrates evidence-based medicine with advanced therapeutic approaches, including immunotherapy and targeted therapy.

• M.B.B.S., Smt. N.H.L. Municipal Medical College, Gujarat University, India
• Internal Medicine Residency, Bridgeport Hospital, Yale School of Medicine, Connecticut, USA
• Hematology/ Oncology Fellowship, University of Connecticut, Farmington, Connecticut, USA
• Bone Marrow Transplantation, Memorial Sloan Kettering, New York, USA ABIM (American Board) Certification
• Board-certified in Internal Medicine (2009)
• Board-certified in Hematology (2012)
• Board-certified in Medical Oncology (2012)

• Senior Consultant, Medical Oncologist, Shalby Cancer and Research Institute, Ahmedabad (Current)
• Consultant, Medical Oncologist and Hematologist, HCG Cancer Centre, Ahmedabad (2015–2026)
• Attending Physician – Lawrence Medical Associates, NewYork-Presbyterian Medical Group Westchester, New York (June 2013-July 2015)
• Clinical Assistant Professor, Department of Medicine/ Hematology- Oncology, University of Connecticut, Farmington, Connecticut (2012)

• Awarded in 2011 by the Connecticut Health Breast Initiative for the research project “Impact of HER2 on the outcomes of patients with small breast cancers”
• Principal Investigator in multiple Phase II & III international oncology trials (2017–2023)
• ABIM Board Certified in Internal Medicine, Hematology & Medical Oncology (USA)

• Indian Society of Pediatric and Medical Oncology (ISMPO)
• European Society of Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• Association of Gynaecologic Oncologists of India (AGOI)
• Immuno Oncology Society of India (I-OSI)

• Prevention and management of solid tumours.
• Special focus on breast and gynaecological malignancies.
• Personalised medicine through genomics, immunotherapy, targeted therapy, and antibody drug conjugates.
• Palliative management.

Published manuscripts

• Shah M, Agarwal B, Recent advances in management of acute myeloid leukemia (AML), Indian J Pediatr. 2008 Aug;75(8):831-7.
• Saif MW, Shah M., K-ras mutations in colorectal cancer: a practice changing discovery, Clin Adv Hematol Oncol. 2009 Jan;7(1):45-64.
• Saif MW, Shah M, Shah A, Fluoropyrimidine associated cardiotoxicity: revisited, Expert Opinion in Drug Safety, 2009 March: 8 (2): 191-202.
• Shah M, Summerhill E, Manthous CA, Medical Professionalism in the New Millennium: Are there intercultural differences?, Conn Med. 2009 May;73(5):289-94.
• Shah M, Saif MW, Pancreatic Cancer and Thrombosis: Highlights from the “2010 ASCO Annual Meeting”. J Pancreas (Online) 2010 Jul YY; 11(4):331-333
• Lucas Z, Shah M, Trivedi A, Dailey M, Hepatoid adenocarcinoma of the peritoneal cavity: Prolonged survival after debulking surgery and 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) therapy; Journal of Gastrointestinal Oncology  2012;3(2):139-142. June 2012
• Rajappa S, Bapna A, Arya D, Desai C, Shah M, Walia M, Real-world treatment patterns and outcomes in Indian patients with HR+/HER2- advanced breast cancer treated with Palbociclib; J Cancer Res Ther. 2026 Jan 1;22(1):97-103.
• Vyas M, Patel S, Shah M, Alurkar S, Beyond the expected: Rare Immune Related Neuromuscular toxicities of Checkpoint Inhibitors – A Real World Experience. IJMPO 2026;00:1-6

Published Abstracts

• Shah M, Hotchkiss S, Shanley J, Davies M., Ferencz T.M., Syrigos K, Saif M, Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC), J Clin Oncol 26: 2008 (May 20 suppl; abstr 15092)
• Shah M, Shah A, Raloxifene and Venous Thromboembolism: A Systematic Review of Randomized Clinical Trials, J Oncol Pharm Practice 14 (2), 2008: 82
• Shah M, Bortezomib associated pulmonary toxicity, J Oncol Pharm Practice 14 (2), 2008: 98
• Shah M, Shah A, Effects of Iron Therapy on Congestive Heart Failure Patients – A Meta-Analysis, Haematologica 2008; 93(s1): 387
• Hirapara P, Shah M, Patel K, Patel V, Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience, ESMO Asia Congress, November 2023; Annals of Oncology 34:S1596
• M. Shah, S. Patel, T. Shah, D. G. Vijay, S. Alurkar. Clinicopathological profile and outcomes in young Indian patients with breast cancer – A single-center experience In: Proceedings of the San Antonio Breast Cancer Symposium 2025; TX. AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-02-23.
• T. N. Shah, V. Devanhalli, M. Shah, M. Bakre. De-escalation of systemic therapy for breast cancer in the Indian Setting: A Proteomics and artificial intelligence based Approach to Risk Stratification beyond Ki67, Tumour Grade, and NPI for HR+/HER2-Negative Breast Cancer. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-09-17.